tiprankstipranks
Soleno Therapeutics Inc (SLNO)
NASDAQ:SLNO
US Market
SLNO
Soleno Therapeutics
RESEARCH TOOLSreports
Want to see SLNO full AI Analyst Report?

Soleno Therapeutics (SLNO) Stock Forecast & Price Target

928 Followers
See the Price Targets and Ratings of:

SLNO Analyst Ratings

Hold
13Ratings
Hold
2 Buy
11 Hold
0 Sell
Based on 13 analysts giving stock ratings to
Soleno
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

SLNO Stock 12 Month Forecast

Average Price Target

$65.50
▲(24.10% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Soleno Therapeutics in the last 3 months. The average price target is $65.50 with a high forecast of $125.00 and a low forecast of $53.00. The average price target represents a 24.10% change from the last price of $52.78.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"35":"$35","126":"$126","57.75":"$57.8","80.5":"$80.5","103.25":"$103.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$125.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":65.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$65.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":53,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$53.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[35,57.75,80.5,103.25,126],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.99,43.760000000000005,50.53,57.3,64.07,70.84,77.61,84.38,91.15,97.91999999999999,104.69,111.46000000000001,118.22999999999999,{"y":125,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.99,39.183076923076925,41.37615384615385,43.56923076923077,45.762307692307694,47.95538461538462,50.14846153846154,52.34153846153846,54.534615384615385,56.72769230769231,58.92076923076923,61.113846153846154,63.30692307692308,{"y":65.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.99,38.221538461538465,39.45307692307693,40.684615384615384,41.91615384615385,43.14769230769231,44.37923076923077,45.610769230769236,46.84230769230769,48.073846153846155,49.30538461538462,50.536923076923074,51.76846153846154,{"y":53,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":68.26,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.02,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.63,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.22,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.12,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.16,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.02,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.3,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.32,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.06,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.99,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$125.00Average Price Target$65.50Lowest Price Target$53.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on SLNO
Derek Archila
Wells Fargo
Wells Fargo
$110→$53
Hold
0.42%
Upside
Downgraded
04/17/26
Soleno Therapeutics downgraded to Equal Weight from Overweight at Wells FargoSoleno Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
LifeSci Capital Analyst forecast on SLNO
Kate Dellorusso
LifeSci Capital
LifeSci Capital
$53
Hold
0.42%
Upside
Reiterated
04/11/26
Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (NASDAQ: ELVN), Viridian Therapeutics (NASDAQ: VRDN) and Soleno Therapeutics (NASDAQ: SLNO)
H.C. Wainwright Analyst forecast on SLNO
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$100→$53
Hold
0.42%
Upside
Downgraded
04/08/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD) and Soleno Therapeutics (NASDAQ: SLNO)
Piper Sandler Analyst forecast on SLNO
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$145→$53
Hold
0.42%
Upside
Downgraded
04/07/26
Soleno Therapeutics downgraded to Neutral from Overweight at Piper SandlerSoleno Therapeutics downgraded to Neutral from Overweight at Piper Sandler
Stifel Nicolaus Analyst forecast on SLNO
James Condulis
Stifel Nicolaus
Stifel Nicolaus
$115→$53
Hold
0.42%
Upside
Downgraded
04/07/26
Soleno Therapeutics downgraded to Hold from Buy at StifelSoleno Therapeutics downgraded to Hold from Buy at Stifel
TD Cowen Analyst forecast on SLNO
Tyler Van Buren
TD Cowen
TD Cowen
$85→$53
Hold
0.42%
Upside
Downgraded
04/06/26
Hold Rating on Soleno Reflects Capped Upside Under Neurocrine Takeover Agreement
Cantor Fitzgerald Analyst forecast on SLNO
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
$123→$53
Hold
0.42%
Upside
Downgraded
04/06/26
Soleno Therapeutics downgraded to Neutral from Overweight at Cantor FitzgeraldSoleno Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
Wolfe Research Analyst forecast on SLNO
Kalpit Patel
Wolfe Research
Wolfe Research
―
Hold
―
Downgraded
04/06/26
Soleno Therapeutics downgraded to Peer Perform from Outperform at Wolfe ResearchSoleno Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research
Oppenheimer Analyst forecast on SLNO
Leland Gershell
Oppenheimer
Oppenheimer
―
Hold
―
Downgraded
04/06/26
Soleno downgraded to Perform from Outperform at OppenheimerSoleno downgraded to Perform from Outperform at Oppenheimer
Laidlaw Analyst forecast on SLNO
Yale Jen
Laidlaw
Laidlaw
―
Hold
―
Downgraded
04/06/26
Soleno Therapeutics downgraded to Hold from Buy at LaidlawSoleno Therapeutics downgraded to Hold from Buy at Laidlaw
Robert W. Baird Analyst forecast on SLNO
Brian Skorney
Robert W. Baird
Robert W. Baird
$107→$53
Hold
0.42%
Upside
Downgraded
04/06/26
Soleno Therapeutics downgraded to Neutral from Outperform at BairdSoleno Therapeutics downgraded to Neutral from Outperform at Baird
Goldman Sachs Analyst forecast on SLNO
Paul Choi
Goldman Sachs
Goldman Sachs
$125
Buy
136.83%
Upside
Reiterated
02/25/26
Analysts Conflicted on These Healthcare Names: PROCEPT BioRobotics (NASDAQ: PRCT), Soleno Therapeutics (NASDAQ: SLNO) and Agilent (NYSE: A)
Guggenheim Analyst forecast on SLNO
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$106
Buy
100.83%
Upside
Reiterated
01/28/26
Guggenheim Keeps Their Buy Rating on Soleno Therapeutics (SLNO)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on SLNO
Derek Archila
Wells Fargo
Wells Fargo
$110→$53
Hold
0.42%
Upside
Downgraded
04/17/26
Soleno Therapeutics downgraded to Equal Weight from Overweight at Wells FargoSoleno Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
LifeSci Capital Analyst forecast on SLNO
Kate Dellorusso
LifeSci Capital
LifeSci Capital
$53
Hold
0.42%
Upside
Reiterated
04/11/26
Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (NASDAQ: ELVN), Viridian Therapeutics (NASDAQ: VRDN) and Soleno Therapeutics (NASDAQ: SLNO)
H.C. Wainwright Analyst forecast on SLNO
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$100→$53
Hold
0.42%
Upside
Downgraded
04/08/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD) and Soleno Therapeutics (NASDAQ: SLNO)
Piper Sandler Analyst forecast on SLNO
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$145→$53
Hold
0.42%
Upside
Downgraded
04/07/26
Soleno Therapeutics downgraded to Neutral from Overweight at Piper SandlerSoleno Therapeutics downgraded to Neutral from Overweight at Piper Sandler
Stifel Nicolaus Analyst forecast on SLNO
James Condulis
Stifel Nicolaus
Stifel Nicolaus
$115→$53
Hold
0.42%
Upside
Downgraded
04/07/26
Soleno Therapeutics downgraded to Hold from Buy at StifelSoleno Therapeutics downgraded to Hold from Buy at Stifel
TD Cowen Analyst forecast on SLNO
Tyler Van Buren
TD Cowen
TD Cowen
$85→$53
Hold
0.42%
Upside
Downgraded
04/06/26
Hold Rating on Soleno Reflects Capped Upside Under Neurocrine Takeover Agreement
Cantor Fitzgerald Analyst forecast on SLNO
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
$123→$53
Hold
0.42%
Upside
Downgraded
04/06/26
Soleno Therapeutics downgraded to Neutral from Overweight at Cantor FitzgeraldSoleno Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
Wolfe Research Analyst forecast on SLNO
Kalpit Patel
Wolfe Research
Wolfe Research
―
Hold
―
Downgraded
04/06/26
Soleno Therapeutics downgraded to Peer Perform from Outperform at Wolfe ResearchSoleno Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research
Oppenheimer Analyst forecast on SLNO
Leland Gershell
Oppenheimer
Oppenheimer
―
Hold
―
Downgraded
04/06/26
Soleno downgraded to Perform from Outperform at OppenheimerSoleno downgraded to Perform from Outperform at Oppenheimer
Laidlaw Analyst forecast on SLNO
Yale Jen
Laidlaw
Laidlaw
―
Hold
―
Downgraded
04/06/26
Soleno Therapeutics downgraded to Hold from Buy at LaidlawSoleno Therapeutics downgraded to Hold from Buy at Laidlaw
Robert W. Baird Analyst forecast on SLNO
Brian Skorney
Robert W. Baird
Robert W. Baird
$107→$53
Hold
0.42%
Upside
Downgraded
04/06/26
Soleno Therapeutics downgraded to Neutral from Outperform at BairdSoleno Therapeutics downgraded to Neutral from Outperform at Baird
Goldman Sachs Analyst forecast on SLNO
Paul Choi
Goldman Sachs
Goldman Sachs
$125
Buy
136.83%
Upside
Reiterated
02/25/26
Analysts Conflicted on These Healthcare Names: PROCEPT BioRobotics (NASDAQ: PRCT), Soleno Therapeutics (NASDAQ: SLNO) and Agilent (NYSE: A)
Guggenheim Analyst forecast on SLNO
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$106
Buy
100.83%
Upside
Reiterated
01/28/26
Guggenheim Keeps Their Buy Rating on Soleno Therapeutics (SLNO)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Soleno Therapeutics

3 Months
xxx
Success Rate
4/5 ratings generated profit
80%
Average Return
+16.96%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +16.96% per trade.
1 Year
Debjit ChattopadhyayGuggenheim
Success Rate
2/5 ratings generated profit
40%
Average Return
+3.50%
Copying Debjit Chattopadhyay's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of +3.50% per trade.
2 Years
xxx
Success Rate
2/5 ratings generated profit
40%
Average Return
+4.32%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 40.00% of your transactions generating a profit, with an average return of +4.32% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SLNO Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
16
23
18
22
11
Buy
0
1
1
1
0
Hold
0
0
0
0
12
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
16
24
19
23
23
In the current month, SLNO has received 11 Buy Ratings, 12 Hold Ratings, and 0 Sell Ratings. SLNO average Analyst price target in the past 3 months is 65.50.
Each month's total comprises the sum of three months' worth of ratings.

SLNO Financial Forecast

SLNO Earnings Forecast

Next quarter’s earnings estimate for SLNO is $0.68 with a range of $0.20 to $0.93. The previous quarter’s EPS was $0.80. SLNO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year SLNO has Performed in-line its overall industry.
Next quarter’s earnings estimate for SLNO is $0.68 with a range of $0.20 to $0.93. The previous quarter’s EPS was $0.80. SLNO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year SLNO has Performed in-line its overall industry.

SLNO Sales Forecast

Next quarter’s sales forecast for SLNO is $93.78M with a range of $66.46M to $100.00M. The previous quarter’s sales results were $91.73M. SLNO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year SLNO has Performed in-line its overall industry.
Next quarter’s sales forecast for SLNO is $93.78M with a range of $66.46M to $100.00M. The previous quarter’s sales results were $91.73M. SLNO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year SLNO has Performed in-line its overall industry.

SLNO Stock Forecast FAQ

What is SLNO’s average 12-month price target, according to analysts?
Based on analyst ratings, Soleno Therapeutics Inc’s 12-month average price target is 65.50.
    What is SLNO’s upside potential, based on the analysts’ average price target?
    Soleno Therapeutics Inc has 24.10% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is SLNO a Buy, Sell or Hold?
          Soleno Therapeutics Inc has a consensus rating of Hold which is based on 2 buy ratings, 11 hold ratings and 0 sell ratings.
            What is Soleno Therapeutics Inc’s price target?
            The average price target for Soleno Therapeutics Inc is 65.50. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $125.00 ,the lowest forecast is $53.00. The average price target represents 24.10% Increase from the current price of $52.78.
              What do analysts say about Soleno Therapeutics Inc?
              Soleno Therapeutics Inc’s analyst rating consensus is a Hold. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of SLNO?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.